Abstract:Programmed cell death 1 receptor (PD-1) on the surface of T cells and its ligand 1 (PD-L1) are immune checkpoint proteins. Treating cancer patients with inhibitors blocking this checkpoint has significantly prolonged the survival rate of patients. In this study, we examined several monoclonal antibodies (mAbs) of PD-L1 and studied their detailed binding mechanism to PD-L1. An efficient computational alanine scanning method was used to perform quantitative analysis of hotspot residues that are important for PD-1/PD-L1 binding. A total of five PD-L1/mAb complexes were investigated and hotspots on both PD-L1 and mAbs were predicted. Our result shows that PD-L1M115 and PD-L1Y123 are two relatively important hotspots in all the five PD-L1/mAb binding complexes. It is also found that the important residues of mAbs binding to PD-L1M115 and PD-L1Y123 are similar to each other. The computational alanine scanning result is compared to the experimental measurements that are available for two of the mAbs (KN035 and atezolizumab). The calculated alanine scanning result is in good agreement with the experimental data with a correlation coefficient of 0.87 for PD-L1/KN035 and 0.6 for PD-L1/atezolizumab. Our computation found more hotspots on PD-L1 in the PD-L1/KN035 complex than those in the PD-L1/atezolizumab system, indicating stronger binding affinity in the former than the latter, which is in good agreement with the experimental finding. The present work provides important insights for the design of new mAbs targeting PD-L1.

Bioengineering and Computational Analysis of Programmed Cell Death Ligand-1 Monoclonal Antibody.

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Engineering of Α-Pd-1 Antibody-Expressing Long-Lived Plasma Cells by CRISPR/Cas9-mediated Targeted Gene Integration

[Construction, Expression and Purification of a Mammalian Secretory Recombinant Fusion Protein Rpc].

A Novel Recombinant Fusion Protein with Soluble PD-1 and TIM-3 Domains Effectively Binds to Cancer Cells

Programmed Cell Death Ligand-1: A Dynamic Immune Checkpoint in Cancer Therapy.

Expression and Purification of Soluble Human Programmed Death-1 in Escherichia Coli.

Expression of a Recombinant Anti-Programed Cell Death 1 Antibody in the Mammary Gland of Transgenic Mice

Preparation and application of anti-human PD-L1 monoclonal antibodies

Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1

Engineered Scpdl1-Dm1 Drug Conjugate with Improved in Vitro Analysis to Target PD-L1 Positive Cancer Cells and Intracellular Trafficking Studies in Cancer Therapy.

Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells.

Residue Specific Binding Mechanisms of PD-1 to Its Monoclonal Antibodies by Computational Alanine Scanning

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)

[Preparation and Identification of Monoclonal Antibodies Against Human Programmed Cell Death 10 (PDCD10)].

Design and Production of a Novel Anti-PD-1 Nanobody by CDR Grafting and Site-Directed Mutagenesis Approach

Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning

In Vitro and in Vivo Degradation of Programmed Cell Death Ligand 1 (PD-L1) by a Proteolysis Targeting Chimera (PROTAC).

PDL1Binder: Identifying Programmed Cell Death Ligand 1 Binding Peptides by Incorporating Next-Generation Phage Display Data and Different Peptide Descriptors.

A Strategy for the Efficient Construction of Anti-Pd1-based Bispecific Antibodies with Desired IgG-like Properties

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy